Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 2;13(1):5794.
doi: 10.1038/s41467-022-33549-6.

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022

Saranya Sridhar  1 , Roman M Chicz  2 , William Warren  3   4 , Jim Tartaglia  3 , Stephen Savarino  3 , Sanjay Gurunathan  3 , Jean-Francois Toussaint  5
Affiliations

The potential of Beta variant containing COVID booster vaccines for chasing Omicron in 2022

Saranya Sridhar et al. Nat Commun. .

Abstract

Currently approved COVID vaccines are designed using the spike antigen derived from the ancestral strain, but health authorities are recommending changes to the vaccine strain to combat emerging variants. The goal is to ensure that next generation vaccines can tackle multiple variants of concern including the most prevalent variant for the coming season. We here discuss recent preclinical and clinical data on COVID vaccine antigens that are potential candidates for an updated vaccine.

PubMed Disclaimer

Conflict of interest statement

All authors are employees of Sanofi and hold stock options. Sanofi is developing a recombinant Beta strain vaccine booster in collaboration with GSK (AS03 adjuvant) and funded in part by Sanofi and the US Government through the Biomedical Advanced Research and Development Authority (BARDA) under contract HHSO100201600005I.

References

    1. Memorandum of 30 Jun 2022—Fall 2022 COVID-19 Vaccine Strain Composition Selection Recommendation. https://www.fda.gov/media/159597/download (2022).
    1. Anderson EM, et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. Cell. 2021;184:1858–1864. doi: 10.1016/j.cell.2021.02.010. - DOI - PMC - PubMed
    1. Yamashita T, et al. Preexisting humoral immunity cross-reacting with SARS-CoV-2 might prevent death due to COVID-19 in critical patients. J. Clin. Med. 2022;11:3870–3880. doi: 10.3390/jcm11133870. - DOI - PMC - PubMed
    1. Grifoni A, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. 2020;181:1489–1501.e15. doi: 10.1016/j.cell.2020.05.015. - DOI - PMC - PubMed
    1. Sagar M, et al. Recent endemic coronavirus infection is associated with less-severe COVID-19. J. Clin. Invest. 2021;131:e143380. doi: 10.1172/JCI143380. - DOI - PMC - PubMed

Supplementary concepts